Insight Genetics selected for NCI’s Clinical Assay Development Program
NASHVILLE, Tenn.—The National Cancer Institute (NCI) has selected Insight Genetics to participate in the Clinical Assay Development Program (CADP), an initiative of the NCI's Division of Cancer Treatment and Diagnosis that seeks to advance promising assays from the lab to clinical trials, based on Insight Genetics' predictive diagnostic test for lung cancer. The Insight ALK Screen provides comprehensive data that reveals whether a patient's cancer is associated with anaplastic lymphoma kinase (ALK) and if it might respond to ALK-inhibitor therapies. ALK fusions and mutations have been found to contribute to roughly 5 to 10 percent of lung cancers. Through the CADP, the NCI will support Insight Genetics by providing clinical sample access, expertise, consultation and the services of two CLIA-certified labs to further validate the assay.